260 related articles for article (PubMed ID: 30849243)
1. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
4. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
6. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen M; Huddart R; Joffe J; Gardiner D; Maynard L; Hutton P; Mazhar D; Shamash J; Wheater M; White J; Goubar A; Porta N; Witts S; Lewis R; Hall E;
Eur Urol; 2020 Mar; 77(3):344-351. PubMed ID: 31901440
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
9. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Rashid S; Lim L; Powles T
Curr Treat Options Oncol; 2012 Jun; 13(2):201-11. PubMed ID: 22623055
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
13. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
Kawai K; Akaza H
Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
[TBL] [Abstract][Full Text] [Related]
14. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
Mezvrishvili Z; Managadze L
Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
[TBL] [Abstract][Full Text] [Related]
15. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
[TBL] [Abstract][Full Text] [Related]
16. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
17. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Farmakis D; Pectasides M; Pectasides D
Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]